Mayne Pharma Pursues ‘Aggressive Rationalization’ To Rally Revenue

Mayne Winds Up Unprofitable Generics In A Bid For Efficiency And Focus

 
• By Rosalind Rei

Mayne’s 2022 results take stock of pivotal changes, with the Australian firm drawing down its generics portfolio as it focuses on the US branded products market. These new priorities come amid a high-value asset sale and a change in CEO.

Businessman financial charts reports
Mayne has pruned its generics portfolio of unprofitable products • Source: Shutterstock

More from Strategy

More from Business